USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) shares reached a new 52-week low during trading on Thursday after DA Davidson lowered their price target on the stock from $38.00 to $36.00. DA Davidson currently has a neutral rating on the stock. USANA Health Sciences traded as low as $29.99 and last traded at $29.65, with a volume of 28871 shares. The stock had previously closed at $33.21.
Other research analysts have also issued research reports about the company. Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th.
Check Out Our Latest Stock Report on USANA Health Sciences
Institutional Trading of USANA Health Sciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new position in shares of USANA Health Sciences in the fourth quarter valued at approximately $28,000. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences in the 3rd quarter valued at $30,000. KBC Group NV increased its stake in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company's stock valued at $40,000 after buying an additional 519 shares during the period. KLP Kapitalforvaltning AS purchased a new position in USANA Health Sciences during the 4th quarter worth $83,000. Finally, Quantbot Technologies LP acquired a new stake in shares of USANA Health Sciences in the 4th quarter worth $132,000. 54.25% of the stock is owned by hedge funds and other institutional investors.
USANA Health Sciences Stock Up 1.3 %
The company's fifty day moving average price is $33.42 and its two-hundred day moving average price is $36.47. The firm has a market cap of $571.21 million, a PE ratio of 10.59, a P/E/G ratio of 0.93 and a beta of 0.87.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to analyst estimates of $208.82 million. As a group, analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Read More
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
